Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey - 19/08/11
, Kathleen M. Fox, PhD b, Vaishali Patel, PharmD, MS c, Chiun-Fang Chiou, PhD c, Frank Dann, MD c, Mark Lebwohl, MD d
Reprint requests: National Psoriasis Foundation, 6600 SW 92nd Ave, Suite 300, Portland, OR 97223-7195.Abstract |
Objective |
We sought to assess whether patients with psoriasis with moderate or severe disease are being treated with systemic therapy.
Methods |
Participants were identified from a random sample of the National Psoriasis Foundation contact database who were 18 years and older, with severe psoriasis (>10% body surface area) and moderate psoriasis (3%-10% body surface area); respondents with psoriatic arthritis were excluded.
Results |
In all, 1657 respondents with psoriasis completed the survey (28% severe, 41% moderate). A total of 39% of respondents with severe psoriasis and 37% with moderate psoriasis were not currently receiving any treatment. Among respondents currently receiving therapy, only 43% of respondents with severe psoriasis received either traditional systemic therapy, biologic therapy, or phototherapy.
Limitations |
Respondents were from the National Psoriasis Foundation contact database and reported their current severity, which may be affected by their treatment. Body surface area as a measure of patient-reported severity has not been validated but has been used in several published studies.
Conclusions |
Almost 40% of respondents with psoriasis were currently not receiving treatment. For respondents with severe psoriasis, 26% were treated with systemic therapy, phototherapy, or both; 39% were not in treatment; and 35% were treated with topical therapy alone.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AAD, BSA, UV
Plan
| The National Psoriasis Foundation funded, designed, and conducted the surveys. Amgen and National Psoriasis Foundation collaborated for the analysis of treatment patterns in individuals with psoriasis. Strategic Healthcare Solutions, an independent consultant, was funded by Amgen for project design, statistical analysis, interpretation of data, drafting the article, and project management. |
|
| Disclosure: At the time of this work, Dr Horn was an employee of the National Psoriasis Foundation. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen, Wyeth, Barrier Therapeutics, Biogen Idec, Centocor, Connetics Corporation, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Photomedex, UVBiotek, Valeant Pharmaceuticals, and Warner Chilcott. Dr Fox is a paid consultant to Amgen. Drs Patel, Chiou, and Dann are employees of Amgen. Dr Lebwohl has been a consultant and/or speaker for Amgen, Abbott, Astellas, Centocor, Genentech, Connetics, Pharmaderm, Novartis, Warner Chilcott, and Galderma Laboratories. |
|
| Presented in abstract and poster form at the Annual Meeting of the American Academy of Dermatology in Washington, DC, on February 3, 2007. |
Vol 57 - N° 6
P. 957-962 - décembre 2007 Retour au numéro
Article précédent
- Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic
- Mark D.P. Davis, Katrina M. Dy, Steven Nelson
- Association of patient-reported psoriasis severity with income and employment
- Elizabeth J. Horn, Kathleen M. Fox, Vaishali Patel, Chiun-Fang Chiou, Frank Dann, Mark Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?